Candel Therapeutics Inc (CADL)
8.90
+0.28
(+3.25%)
USD |
NASDAQ |
May 31, 16:00
9.00
+0.10
(+1.12%)
After-Hours: 20:00
Candel Therapeutics Enterprise Value: 258.74M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 258.74M |
| May 30, 2024 | 250.41M |
| May 29, 2024 | 255.46M |
| May 28, 2024 | 248.33M |
| May 24, 2024 | 226.02M |
| May 23, 2024 | 311.98M |
| May 22, 2024 | 308.71M |
| May 21, 2024 | 358.98M |
| May 20, 2024 | 350.35M |
| May 17, 2024 | 336.07M |
| May 16, 2024 | 371.77M |
| May 15, 2024 | 410.43M |
| May 14, 2024 | 312.28M |
| May 13, 2024 | 297.40M |
| May 10, 2024 | 271.23M |
| May 09, 2024 | 290.56M |
| May 08, 2024 | 316.14M |
| May 07, 2024 | 279.26M |
| May 06, 2024 | 257.25M |
| May 03, 2024 | 258.72M |
| May 02, 2024 | 241.41M |
| May 01, 2024 | 228.20M |
| April 30, 2024 | 200.91M |
| April 29, 2024 | 182.13M |
| April 26, 2024 | 181.54M |
| Date | Value |
|---|---|
| April 25, 2024 | 182.71M |
| April 24, 2024 | 171.56M |
| April 23, 2024 | 167.45M |
| April 22, 2024 | 156.59M |
| April 19, 2024 | 145.74M |
| April 18, 2024 | 154.25M |
| April 17, 2024 | 153.66M |
| April 16, 2024 | 166.87M |
| April 15, 2024 | 164.81M |
| April 12, 2024 | 189.46M |
| April 11, 2024 | 207.66M |
| April 10, 2024 | 143.68M |
| April 09, 2024 | 143.39M |
| April 08, 2024 | 182.71M |
| April 05, 2024 | 188.88M |
| April 04, 2024 | 181.83M |
| April 03, 2024 | 43.31M |
| April 02, 2024 | 43.61M |
| April 01, 2024 | 45.37M |
| March 28, 2024 | 32.23M |
| March 27, 2024 | 31.06M |
| March 26, 2024 | 29.59M |
| March 25, 2024 | 30.47M |
| March 22, 2024 | 29.88M |
| March 21, 2024 | 28.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-13.68M
Minimum
Oct 20 2022
410.43M
Maximum
May 15 2024
60.48M
Average
27.19M
Median
Enterprise Value Benchmarks
| Allurion Technologies Inc | 81.68M |
| AngioDynamics Inc | 174.29M |
| Eliem Therapeutics Inc | 115.77M |
| Macrogenics Inc | 71.31M |
| GlycoMimetics Inc | -13.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.221M |
| Total Expenses (Quarterly) | 7.902M |
| EPS Diluted (Quarterly) | -0.28 |
| Earnings Yield | -14.38% |
| Normalized Earnings Yield | -13.70 |